Physician profile
Vincent A Bertomeu
NPI 1003074139
$5,926.59
in general payments reported to CMS, 2019-2025
19 companies · $813 in 2025
The $813 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,177 · 2020: $262 · 2021: $477 · 2022: $846 · 2023: $994 · 2024: $1,356 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,031 · Entertainment: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,030.77 |
| Entertainment | $133.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,368.06 | 2019-2025 | Precision 1, Total30, Dailies Total1 |
| Coopervision INC. | $735.41 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Bausch & Lomb Americas INC. | $623.27 | 2022-2025 | Infuse, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $512.34 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $231.42 | 2023-2024 | Cequa |
| Rxsight INC | $181.86 | 2022-2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Optos, INC. | $176.44 | 2019-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Kala Pharmaceuticals, INC. | $152.19 | 2021 | |
| Dompe US, INC. | $121.81 | 2023 | Oxervate |
| Maculogix, INC. | $117.92 | 2020 | |
| Harrow Eye, LLC | $113.51 | 2025 | Vevye |
| Sight Sciences, INC. | $111.74 | 2024 | Omni Surgical System |
| Glaukos Corporation | $104.07 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $102.22 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $100.00 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $92.32 | 2024 | |
| Carl Zeiss Meditec, INC. | $43.65 | 2019 | |
| Allergan, INC. | $20.20 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Bertomeu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.